SynOx Therapeutics

Executive Summary

SynOx Therapeutics is a UK-based private biopharmaceutical company singularly focused on developing emactuzumab, a monoclonal antibody targeting colony-stimulating factor 1 receptor (CSF-1R), for the treatment of tenosynovial giant cell tumor (TGCT) and other macrophage-driven diseases. Leveraging a well-characterized mechanism of action, emactuzumab has demonstrated promising efficacy in earlier clinical trials, offering a potential new standard of care for patients with TGCT who have limited treatment options. The company is now advancing emactuzumab through late-stage development, aiming to address significant unmet medical needs in oncology and beyond. SynOx's clinical strategy centers on a pivotal Phase 3 trial for TGCT, with top-line data expected in the near term. Pending positive results, the company plans to pursue regulatory filings in major markets, potentially positioning emactuzumab as a first-in-class therapy for this orphan disease. Additionally, SynOx is exploring the drug's utility in other macrophage-driven conditions, broadening its pipeline. With a focused approach and strong scientific rationale, the company represents a compelling investment opportunity.

Upcoming Catalysts (preview)

• Q3 2026Top-line Phase 3 Data for Emactuzumab in TGCT70% success
• Q1 2027Regulatory Submission (FDA/EMA) for TGCT60% success
• H2 2026Partnership or Licensing Deal for Emactuzumab in Opportunistic Indications50% success